301 related articles for article (PubMed ID: 27695288)
21. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):450-456. PubMed ID: 30504345
[TBL] [Abstract][Full Text] [Related]
22. Eltrombopag added to immunosuppression for children with treatment-naïve severe aplastic anaemia.
Groarke EM; Patel BA; Gutierrez-Rodrigues F; Rios O; Lotter J; Baldoni D; St Pierre A; Shalhoub R; Wu CO; Townsley DM; Young NS
Br J Haematol; 2021 Feb; 192(3):605-614. PubMed ID: 33410523
[TBL] [Abstract][Full Text] [Related]
23. Management of aplastic anemia after failure of frontline immunosuppression.
Pierri F; Dufour C
Expert Rev Hematol; 2019 Oct; 12(10):809-819. PubMed ID: 31311355
[No Abstract] [Full Text] [Related]
24. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug.
Desmond R; Townsley DM; Dumitriu B; Olnes MJ; Scheinberg P; Bevans M; Parikh AR; Broder K; Calvo KR; Wu CO; Young NS; Dunbar CE
Blood; 2014 Mar; 123(12):1818-25. PubMed ID: 24345753
[TBL] [Abstract][Full Text] [Related]
25. Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia.
Assi R; Garcia-Manero G; Ravandi F; Borthakur G; Daver NG; Jabbour E; Burger J; Estrov Z; Dinardo CD; Alvarado Y; Hendrickson S; Ferrajoli A; Wierda W; Cortes J; Kantarjian H; Kadia TM
Cancer; 2018 Nov; 124(21):4192-4201. PubMed ID: 30307606
[TBL] [Abstract][Full Text] [Related]
26. Activity of eltrombopag in severe aplastic anemia.
Scheinberg P
Blood Adv; 2018 Nov; 2(21):3054-3062. PubMed ID: 30425070
[TBL] [Abstract][Full Text] [Related]
27. Novel therapeutic choices in immune aplastic anemia.
Scheinberg P
F1000Res; 2020; 9():. PubMed ID: 32953089
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of avatrombopag in combination with immunosuppressive therapy in treatment-naïve and relapsed/refractory severe aplastic anaemia: protocol for the DIAAMOND-Ava-FIRST and DIAAMOND-Ava-NEXT Bayesian Optimal Phase II trials.
McQuilten Z; Heritier S; Fox L; Fox V; Young L; Blombery P; Cunningham I; Curnow J; Higgins A; Hiwase DK; Filshie R; Firkin F; Lacaze P; Mason K; Mills AK; Pepperell D; Patil S; Stevenson W; Szer J; Waters N; Wilson K; Ting S; Wood E
BMJ Open; 2024 Jan; 14(1):e076246. PubMed ID: 38238183
[TBL] [Abstract][Full Text] [Related]
29. Real-world outcomes with immunosuppressive therapy for aplastic anemia in patients treated at the University of Michigan.
Foucar CE; Foley DH; Aldous J; Burke PW; Pettit KR; Benitez LL; Perissinotti AJ; Marini BL; Boonstra P; Bixby DL
Eur J Haematol; 2024 Mar; 112(3):424-432. PubMed ID: 37929654
[TBL] [Abstract][Full Text] [Related]
30. [Eltrombopag combined with cyclosporine alone for treatment of very severe aplastic anemia: a case report].
Cheng H; Wang X; Xu KL
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):612. PubMed ID: 32397030
[No Abstract] [Full Text] [Related]
31. A real-word experience of eltrombopag plus rabbit antithymocyte immunoglobulin-based IST in Chinese patients with severe aplastic anemia.
Jin Y; Li R; Lin S; Jia J; Yang Y; Zhang D; He G; Li J
Ann Hematol; 2022 Nov; 101(11):2413-2419. PubMed ID: 36028583
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag in the management of aplastic anaemia: real-world experience in a non-trial setting.
Hwang YY; Gill H; Chan TSY; Leung GMK; Cheung CYM; Kwong YL
Hematology; 2018 Aug; 23(7):399-404. PubMed ID: 29303047
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study.
Patel BA; Groarke EM; Lotter J; Shalhoub R; Gutierrez-Rodrigues F; Rios O; Quinones Raffo D; Wu CO; Young NS
Blood; 2022 Jan; 139(1):34-43. PubMed ID: 34525188
[TBL] [Abstract][Full Text] [Related]
34. Deficit of circulating CD19
Zaimoku Y; Patel BA; Kajigaya S; Feng X; Alemu L; Quinones Raffo D; Groarke EM; Young NS
Br J Haematol; 2020 Aug; 190(4):610-617. PubMed ID: 32311088
[TBL] [Abstract][Full Text] [Related]
35. Eltrombopag preferentially expands haematopoietic multipotent progenitors in human aplastic anaemia.
Quintino de Oliveira B; Catto LFB; Santana BAA; Tellechea MF; Scheucher PS; Scheinberg P; Calado RT
Br J Haematol; 2021 Apr; 193(2):410-414. PubMed ID: 33216370
[TBL] [Abstract][Full Text] [Related]
36. Eltrombopag and improved hematopoiesis in refractory aplastic anemia.
Olnes MJ; Scheinberg P; Calvo KR; Desmond R; Tang Y; Dumitriu B; Parikh AR; Soto S; Biancotto A; Feng X; Lozier J; Wu CO; Young NS; Dunbar CE
N Engl J Med; 2012 Jul; 367(1):11-9. PubMed ID: 22762314
[TBL] [Abstract][Full Text] [Related]
37. The thrombopoietin mimetics eltrombopag and romiplostim in the treatment of refractory aplastic anaemia.
Gill H; Leung GM; Lopes D; Kwong YL
Br J Haematol; 2017 Mar; 176(6):991-994. PubMed ID: 27097929
[No Abstract] [Full Text] [Related]
38. Efficacy and Safety of Eltrombopag for Aplastic Anemia: A Systematic Review and Meta-analysis.
Hong Y; Li X; Wan B; Li N; Chen Y
Clin Drug Investig; 2019 Feb; 39(2):141-156. PubMed ID: 30406906
[TBL] [Abstract][Full Text] [Related]
39. [Acquired aplastic anemia: recent advances in pathophysiology and treatment].
Yamazaki H
Rinsho Ketsueki; 2018; 59(6):711-715. PubMed ID: 29973449
[TBL] [Abstract][Full Text] [Related]
40. First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemia.
Peinemann F; Bartel C; Grouven U
Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006407. PubMed ID: 23881658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
